NASDAQ:OSUR

OraSure Technologies Competitors

$10.32
0.00 (0.00 %)
(As of 04/14/2021 12:09 PM ET)
Add
Compare
Today's Range
$10.30
Now: $10.32
$10.47
50-Day Range
$9.53
MA: $10.88
$11.68
52-Week Range
$9.46
Now: $10.32
$19.75
Volume6,056 shs
Average Volume1.11 million shs
Market Capitalization$742.48 million
P/E RatioN/A
Dividend YieldN/A
Beta0.04

Competitors

OraSure Technologies (NASDAQ:OSUR) Vs. ALGN, WST, COO, XRAY, HAE, and QDEL

Should you be buying OSUR stock or one of its competitors? Companies in the sub-industry of "health care supplies" are considered alternatives and competitors to OraSure Technologies, including Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), and Quidel (QDEL).

Align Technology (NASDAQ:ALGN) and OraSure Technologies (NASDAQ:OSUR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Institutional & Insider Ownership

85.8% of Align Technology shares are owned by institutional investors. Comparatively, 98.1% of OraSure Technologies shares are owned by institutional investors. 1.2% of Align Technology shares are owned by insiders. Comparatively, 1.7% of OraSure Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Align Technology and OraSure Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Align Technology13902.62
OraSure Technologies02402.67

Align Technology currently has a consensus target price of $501.3333, suggesting a potential downside of 15.03%. OraSure Technologies has a consensus target price of $17.50, suggesting a potential upside of 69.25%. Given OraSure Technologies' stronger consensus rating and higher possible upside, analysts plainly believe OraSure Technologies is more favorable than Align Technology.

Profitability

This table compares Align Technology and OraSure Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Align Technology76.00%68.99%46.64%
OraSure Technologies-9.05%-3.51%-3.13%

Earnings and Valuation

This table compares Align Technology and OraSure Technologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Align Technology$2.41 billion19.51$442.78 million$4.96119.63
OraSure Technologies$154.60 million4.80$16.66 million$0.1379.38

Align Technology has higher revenue and earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Align Technology has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.

Summary

Align Technology beats OraSure Technologies on 10 of the 14 factors compared between the two stocks.

West Pharmaceutical Services (NYSE:WST) and OraSure Technologies (NASDAQ:OSUR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Institutional & Insider Ownership

92.6% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 98.1% of OraSure Technologies shares are owned by institutional investors. 1.6% of West Pharmaceutical Services shares are owned by insiders. Comparatively, 1.7% of OraSure Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for West Pharmaceutical Services and OraSure Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
West Pharmaceutical Services01202.67
OraSure Technologies02402.67

West Pharmaceutical Services currently has a consensus target price of $310.00, suggesting a potential upside of 2.51%. OraSure Technologies has a consensus target price of $17.50, suggesting a potential upside of 69.25%. Given OraSure Technologies' higher possible upside, analysts plainly believe OraSure Technologies is more favorable than West Pharmaceutical Services.

Profitability

This table compares West Pharmaceutical Services and OraSure Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
West Pharmaceutical Services14.69%19.01%12.78%
OraSure Technologies-9.05%-3.51%-3.13%

Earnings and Valuation

This table compares West Pharmaceutical Services and OraSure Technologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$1.84 billion12.14$241.70 million$3.2493.39
OraSure Technologies$154.60 million4.80$16.66 million$0.1379.38

West Pharmaceutical Services has higher revenue and earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

West Pharmaceutical Services has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.

Summary

West Pharmaceutical Services beats OraSure Technologies on 9 of the 13 factors compared between the two stocks.

The Cooper Companies (NYSE:COO) and OraSure Technologies (NASDAQ:OSUR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Institutional & Insider Ownership

95.8% of The Cooper Companies shares are owned by institutional investors. Comparatively, 98.1% of OraSure Technologies shares are owned by institutional investors. 1.4% of The Cooper Companies shares are owned by insiders. Comparatively, 1.7% of OraSure Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for The Cooper Companies and OraSure Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Cooper Companies04602.60
OraSure Technologies02402.67

The Cooper Companies currently has a consensus target price of $384.25, suggesting a potential downside of 1.22%. OraSure Technologies has a consensus target price of $17.50, suggesting a potential upside of 69.25%. Given OraSure Technologies' stronger consensus rating and higher possible upside, analysts plainly believe OraSure Technologies is more favorable than The Cooper Companies.

Profitability

This table compares The Cooper Companies and OraSure Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Cooper Companies9.81%12.79%7.20%
OraSure Technologies-9.05%-3.51%-3.13%

Earnings and Valuation

This table compares The Cooper Companies and OraSure Technologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Cooper Companies$2.43 billion7.85$238.40 million$9.6440.25
OraSure Technologies$154.60 million4.80$16.66 million$0.1379.38

The Cooper Companies has higher revenue and earnings than OraSure Technologies. The Cooper Companies is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

The Cooper Companies has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.

Summary

The Cooper Companies beats OraSure Technologies on 10 of the 14 factors compared between the two stocks.

DENTSPLY SIRONA (NASDAQ:XRAY) and OraSure Technologies (NASDAQ:OSUR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Risk and Volatility

DENTSPLY SIRONA has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.

Earnings and Valuation

This table compares DENTSPLY SIRONA and OraSure Technologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DENTSPLY SIRONA$4.03 billion3.53$262.90 million$2.4526.51
OraSure Technologies$154.60 million4.80$16.66 million$0.1379.38

DENTSPLY SIRONA has higher revenue and earnings than OraSure Technologies. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DENTSPLY SIRONA and OraSure Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DENTSPLY SIRONA-1.40%7.13%4.13%
OraSure Technologies-9.05%-3.51%-3.13%

Analyst Ratings

This is a breakdown of recent recommendations for DENTSPLY SIRONA and OraSure Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DENTSPLY SIRONA15702.46
OraSure Technologies02402.67

DENTSPLY SIRONA currently has a consensus target price of $55.3333, suggesting a potential downside of 14.77%. OraSure Technologies has a consensus target price of $17.50, suggesting a potential upside of 69.25%. Given OraSure Technologies' stronger consensus rating and higher possible upside, analysts plainly believe OraSure Technologies is more favorable than DENTSPLY SIRONA.

Institutional & Insider Ownership

96.0% of DENTSPLY SIRONA shares are owned by institutional investors. Comparatively, 98.1% of OraSure Technologies shares are owned by institutional investors. 0.5% of DENTSPLY SIRONA shares are owned by insiders. Comparatively, 1.7% of OraSure Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

DENTSPLY SIRONA beats OraSure Technologies on 8 of the 14 factors compared between the two stocks.

OraSure Technologies (NASDAQ:OSUR) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.

Volatility & Risk

OraSure Technologies has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.

Earnings & Valuation

This table compares OraSure Technologies and Haemonetics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OraSure Technologies$154.60 million4.80$16.66 million$0.1379.38
Haemonetics$988.48 million6.03$76.53 million$3.3135.42

Haemonetics has higher revenue and earnings than OraSure Technologies. Haemonetics is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares OraSure Technologies and Haemonetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OraSure Technologies-9.05%-3.51%-3.13%
Haemonetics11.76%22.85%10.40%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for OraSure Technologies and Haemonetics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OraSure Technologies02402.67
Haemonetics00403.00

OraSure Technologies presently has a consensus price target of $17.50, suggesting a potential upside of 69.25%. Haemonetics has a consensus price target of $144.80, suggesting a potential upside of 23.33%. Given OraSure Technologies' higher possible upside, research analysts plainly believe OraSure Technologies is more favorable than Haemonetics.

Insider and Institutional Ownership

98.1% of OraSure Technologies shares are owned by institutional investors. Comparatively, 96.2% of Haemonetics shares are owned by institutional investors. 1.7% of OraSure Technologies shares are owned by company insiders. Comparatively, 1.6% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Haemonetics beats OraSure Technologies on 10 of the 13 factors compared between the two stocks.

OraSure Technologies (NASDAQ:OSUR) and Quidel (NASDAQ:QDEL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.

Volatility & Risk

OraSure Technologies has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, Quidel has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.

Earnings & Valuation

This table compares OraSure Technologies and Quidel's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OraSure Technologies$154.60 million4.80$16.66 million$0.1379.38
Quidel$534.89 million10.19$72.92 million$2.7347.17

Quidel has higher revenue and earnings than OraSure Technologies. Quidel is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares OraSure Technologies and Quidel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OraSure Technologies-9.05%-3.51%-3.13%
Quidel36.91%63.31%40.55%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for OraSure Technologies and Quidel, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OraSure Technologies02402.67
Quidel10302.50

OraSure Technologies presently has a consensus price target of $17.50, suggesting a potential upside of 69.25%. Quidel has a consensus price target of $262.75, suggesting a potential upside of 104.41%. Given Quidel's higher possible upside, analysts plainly believe Quidel is more favorable than OraSure Technologies.

Insider and Institutional Ownership

98.1% of OraSure Technologies shares are owned by institutional investors. Comparatively, 84.0% of Quidel shares are owned by institutional investors. 1.7% of OraSure Technologies shares are owned by company insiders. Comparatively, 14.1% of Quidel shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Quidel beats OraSure Technologies on 11 of the 14 factors compared between the two stocks.


OraSure Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Align Technology logo
ALGN
Align Technology
1.9$593.36flat$47.14 billion$2.41 billion27.00
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$302.58flat$22.63 billion$1.84 billion79.84
The Cooper Companies logo
COO
The Cooper Companies
1.9$388.04flat$19.21 billion$2.43 billion80.67
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$64.96flat$13.99 billion$4.03 billion-282.43Decrease in Short Interest
Haemonetics logo
HAE
Haemonetics
1.6$117.23flat$5.97 billion$988.48 million56.63
Quidel logo
QDEL
Quidel
2.4$128.78flat$5.48 billion$534.89 million15.12
STAAR Surgical logo
STAA
STAAR Surgical
1.4$116.63flat$5.38 billion$150.18 million613.87Increase in Short Interest
Neogen logo
NEOG
Neogen
1.2$93.54flat$4.99 billion$418.17 million82.05
ICU Medical logo
ICUI
ICU Medical
1.5$208.17flat$4.37 billion$1.27 billion55.07Insider Selling
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.86flat$3.39 billion$994.85 million-116.71
Atrion logo
ATRI
Atrion
1.1$645.10flat$1.18 billion$155.07 million36.34
Cerus logo
CERS
Cerus
1.7$6.32flat$1.05 billion$74.65 million-16.20News Coverage
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$24.19flat$1.05 billion$253.67 million22.40
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.05flat$679.37 million$123.86 million67.51
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$41.28flat$579.22 million$114.51 million-87.83Gap Down
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$88.57flat$317.93 million$46.90 million27.94
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.